Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
NCT ID: NCT05279924
Last Updated: 2022-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2021-07-01
2022-10-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.
NCT03054662
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
NCT06155955
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
NCT06104826
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
NCT03932201
Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A
NCT02362581
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Duration of the study: 1 year after initiation of prophylaxis with Emicizumab
Inclusion criteria: boys aged \> 2 years, affected with severe hemophilia A with or without inhibitors
Evaluated outcomes: annual bleeding rate, days of absence from school, the need for additional facteur VIII consumption, satisfaction about the treatment and quality of life.
Tools used to assess quality of life are the Ivoirian version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool version 2 (CHO-KLAT) and EQ-5D
The satisfaction of the parents will be assessed using the patients' global impression of change scale (PGIC).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivoirian Boys with severe Hemophilia A treated with Emicizumab
All Ivoirian boys with severe Hemophilia A (with and without inhibitors) on prophylaxis with Emicizumab
Prophylaxis with Emicizumab
Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prophylaxis with Emicizumab
Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
2 Years
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lambert Catherine
Clinical Professor. Hematology department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
N'Dogomo Meité, MD
Role: PRINCIPAL_INVESTIGATOR
CHU de Cocody
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Yopougon
Abidjan, , Côte d’Ivoire
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
001-22/MSHPCMU/CNESVS-km
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.